BMS-986165 is a selective, potent, allosteric inhibitor of tyrosine kinase 2 (Tyk2).

BMS-986020 is an LPA1 antagonist.

BMS-911543 is a potent and selective inhibitor of JAK2 with IC50 of 1.1 nM, approximately 350-, 75- and 65-fold selective to JAK1, JAK3 and TYK2, respectively.

BMS-813160 is a dual CCR2/CCR5 chemokine antagonist.

BMS-777607 is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3 with IC50 of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM.

BMS-754807 is a potent and reversible inhibitor of IGF-1R/IR family kinases, inhibits IGF-1R, IR, Met, TrkA and TrkB with IC50 of 1.8 nM, 1.7 nM, 5.6 nM, 7.4 nM and 4.1 nM, respectively.

BMS687453 is a potent and selective peroxisome proliferator activated receptor (PPAR) α agonist, with an EC50 of 10 nM for human PPARα and ∼410-fold selectivity vs human PPARγ in PPAR-GAL4 transactivation assays.

BMS-626529 is a novel small-molecule attachment inhibitor that targets HIV-1 gp120 and prevents its binding to CD4+ T-cells.

BMS-599626 (AC480) is a selective and efficacious inhibitor of HER1 and HER2 with IC50 of 20 nM and 30 nM, respectively.

BMS-582949 is a dual action p38 Kinase Inhibitor.

BMS-536924 is an ATP-competitive IGF-1R inhibitor with IC50 of 100 nM, modest activity for Mek, Fak, and Lck with very little activity for Akt1, MAPK1/2.

BMS-5 is a potent inhibitor of the LIM kinase. It has IC50 values of 7nM and 8 nM for LIMK1 and LIMK2 respectively.

BMS-345541 is a highly selective inhibitor of the catalytic subunits of IKK-2 and IKK-1 with IC50 of 0.3 μM and 4 μM, respectively.

BMS309403 is orally active, reducing atherosclerosis in mice lacking apoplipoprotein E.

BMS-303141 is a potent ATP-citrate lyase (ACL) inhibitor with IC50 value of 0.13 uM (human recombinant ACL).

BMS-3 is a potent inhibitor of the LIM kinase. It has IC50's of 5nM and 6 nM for LIMK1 and LIMK2 respectively.

BMS-1166 is a potent PD-1/PD-L1 interaction inhibitor with an IC50 of 1.4 nM.

BMS 833923 is an orally bioavailable inhibitor of Smo. It blocks binding of BODIPY cyclopamine (IC50 = 21 nM) and inhibits Gli activation in cell lines that express wild-type Smo or activated mutant forms of Smo (IC50s = 6-35 nM). BMS 833923 robustly inhi

BMN 673 is a novel PARP inhibitor with IC50 of 0.58 nM.

BML-210 is the novel HDAC inhibitor, and its mechanism of action has not been characterized.

BMH-21 is a small molecule DNA intercalator that binds ribosomal DNA and inhibits RNA polymerase I transcription; does not cause phosphorylation of H2AX.

BLU9931 is the first selective small molecule inhibitor of FGFR4 with IC50 of 3 nM; less potent for FGFR1/2/3(IC50> 150 nM).

BLU-782 (BLU782) is a novel potent, selective inhibitor of Activin receptor-like kinase (ALK2) mutant R206H with binding IC50 of <10 Nm.

BLU-554 is a potent fibroblast growth factor receptor 4 (FGFR4) inhibitor.

Bleomycin sulfate (Blenoxane) is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.

BKM120 is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ.

BIX02188 is a selective inhibitor of MEK5 with IC50 of 4.3 nM, also inhibits ERK5 catalytic activity with IC50 of 810 nM, and does not inhibit closely related kinases MEK1, MEK2, ERK2, and JNK2.

BIX01294 is an inhibitor of G9a histone methyltransferase with IC50 of 2.7 μM.

Bisindolylmaleimide X is a cell-permeable, reversible, ATP-competitive protein kinase C (PKC) inhibitor (IC50 = 15 nM, rat brain PKC).

Bisantrene is a highly effective antitumor drug, targets eukaryotic type II topoisomerases.